A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

Saved in:
Bibliographic Details
Published in:American journal of hematology 2019-12, Vol.94 (12), p.E319-E322
Main Authors: Lee, Hans C., Shah, Jatin J., Feng, Lei, Morphey, Ashley, Johnson, Ralph J., Wesson, Emily T., Wang, Michael L., Alexanian, Raymond, Thomas, Sheeba K., Orlowski, Robert Z., Weber, Donna M.
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Dexamethasone
Dexamethasone - administration & dosage
Dexamethasone - adverse effects
Drug Resistance, Neoplasm
Female
Hematology
Humans
Immunotherapy
Lenalidomide - administration & dosage
Lenalidomide - adverse effects
Male
Maximum Tolerated Dose
Middle Aged
Multiple myeloma
Multiple Myeloma - drug therapy
Progression-Free Survival
Recurrence
Salvage Therapy
Steroids
Targeted cancer therapy
Thalidomide
Thalidomide - administration & dosage
Thalidomide - adverse effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0361-8609
1096-8652
DOI:10.1002/ajh.25633